Literature DB >> 11583211

Carriage of Staphylococcus aureus and of gram-negative bacilli resistant to third-generation cephalosporins in cirrhotic patients: a prospective assessment of hospital-acquired infections.

C Dupeyron1, S B Campillo, N Mangeney, J P Richardet, G Leluan.   

Abstract

OBJECTIVE: To study the relation between Staphylococcus aureus nasal and stool colonization, stool carriage of gram-negative bacilli resistant to third-generation cephalosporins (CephR), and subsequent infections during hospitalization.
DESIGN: Prospective study. PATIENTS: 551 cirrhotic patients with 589 consecutive hospital stays. All patients were screened within 48 hours of admission; 589 nasal swabs, 417 stool specimens, and 589 urine samples were analyzed.
RESULTS: Carriage rates were 18.8% for methicillin-sensitive S aureus (MSSA), 16.3% for methicillin-resistant S aureus (MRSA), and 13.7% for CephR. We observed 87 episodes of spontaneous bacterial peritonitis, 63 cases of bacteremia, and 167 urinary tract infections occurred. Only 1 case of bacteremia and 4 urinary tract infections due to CephR occurred in patients carrying the same organism in their stools. The risk of MRSA ascitic fluid infections, bacteremia, and urinary tract infections was 3.1% versus 1% (not significant), 8.3% versus 0.8% (P<.001), and 11.4% versus 0.6% (P<.001) in carriers and noncarriers, respectively. Pulsed-field gel electrophoresis (PFGE) of isolates from 16 patients infected by MSSA (3 cases) and MRSA (13 cases) demonstrated that the colonizing strains matched the invasive strains in the 3 MSSA cases and in 8 of 13 MRSA cases.
CONCLUSION: Carriage of CephR strains is not associated with subsequent infection by these organisms in hospitalized cirrhotic patients. In contrast, MRSA carriage was an important risk factor for MRSA bacteremia and urinary tract infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583211     DOI: 10.1086/501929

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  6 in total

Review 1.  Quantifying the impact of extranasal testing of body sites for methicillin-resistant Staphylococcus aureus colonization at the time of hospital or intensive care unit admission.

Authors:  James A McKinnell; Susan S Huang; Samantha J Eells; Eric Cui; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-12-21       Impact factor: 3.254

2.  Impact of Probiotics for Reducing Infections in Veterans (IMPROVE): Study protocol for a double-blind, randomized controlled trial to reduce carriage of Staphylococcus aureus.

Authors:  Shoshannah Eggers; Anna Barker; Susan Valentine; Timothy Hess; Megan Duster; Nasia Safdar
Journal:  Contemp Clin Trials       Date:  2016-11-09       Impact factor: 2.226

3.  Clinical significance of Staphylococcus aureus bacteremia in patients with liver cirrhosis.

Authors:  H J Park; Y-M Lee; K M Bang; S-Y Park; S M Moon; K-H Park; Y P Chong; S-H Kim; S-O Lee; S-H Choi; J-Y Jeong; J H Woo; Y S Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-26       Impact factor: 3.267

Review 4.  Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality.

Authors:  Taohua Liu; Yuezhong Zhang; Qiquan Wan
Journal:  Infect Drug Resist       Date:  2018-05-03       Impact factor: 4.003

Review 5.  Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis.

Authors:  Yong-Tao Li; Jian-Rong Huang; Mei-Lian Peng
Journal:  Biomed Res Int       Date:  2020-07-06       Impact factor: 3.411

6.  Staphylococcus aureus isolates colonizing and infecting cirrhotic and liver-transplantation patients: comparison of molecular typing and virulence factors.

Authors:  Larissa Marques de Oliveira; Inneke Marie van der Heijden; George R Golding; Edson Abdala; Maristela P Freire; Flavia Rossi; Luiz C D' alburquerque; Anna S Levin; Silvia F Costa
Journal:  BMC Microbiol       Date:  2015-11-14       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.